Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
Revenue (Most Recent Fiscal Year) | $731.97M |
Net Income (Most Recent Fiscal Year) | $159.52M |
PE Ratio (Current Year Earnings Estimate) | 9.88 |
PE Ratio (Trailing 12 Months) | 9.96 |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 1.96 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.90 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 6.09 |
Pre-Tax Margin (Trailing 12 Months) | 22.40% |
Net Margin (Trailing 12 Months) | 18.64% |
Return on Equity (Trailing 12 Months) | 20.76% |
Return on Assets (Trailing 12 Months) | 9.68% |
Current Ratio (Most Recent Fiscal Quarter) | 3.29 |
Quick Ratio (Most Recent Fiscal Quarter) | 2.21 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.80 |
Inventory Turnover (Trailing 12 Months) | 2.19 |
Book Value per Share (Most Recent Fiscal Quarter) | $16.29 |
Earnings per Share (Most Recent Fiscal Quarter) | $0.75 |
Earnings per Share (Most Recent Fiscal Year) | $3.49 |
Diluted Earnings per Share (Trailing 12 Months) | $2.67 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Common Shares Outstanding | 46.49M |
Free Float | 33.71M |
Market Capitalization | $1.42B |
Average Volume (Last 20 Days) | 0.65M |
Beta (Past 60 Months) | 0.76 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 27.50% |
Percentage Held By Institutions (Latest 13F Reports) | 65.09% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |